Stay updated with breaking news from Andrew Baum. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NEW YORK, Dec 14 ― Pfizer yesterday forecast 2024 sales that could be as much as US$5 billion (RM23.5 billion) below Wall Street expectations, a move top executives said...
Revenue from Pfizer's COVID-19 vaccine and treatment, which peaked at $57 billion in 2022, are now expected to be $8 billion in 2024, a further drop from the $13 billion analysts' forecast and Pfizer's own lowered view of $12.5 billion for this year.
Revenue from Pfizer's COVID-19 vaccine and treatment, which peaked at $57 billion in 2022, are now expected to be $8 billion in 2024, a further drop from the $13 billion analysts' forecast and Pfizer's own lowered view of $12.5 billion for this year.
Pfizer, Inc. on Wednesday forecast 2024 sales that could be as much as $5 billion below Wall Street expectations, driving shares down 9% to a 10-year low.